Skip to main content

Besivance FDA Approval History

FDA Approved: Yes (First approved May 28, 2009)
Brand name: Besivance
Generic name: besifloxacin
Dosage form: Ophthalmic Suspension
Company: Bausch & Lomb Inc.
Treatment for: Conjunctivitis, Bacterial

Besivance (besifloxacin ophthalmic suspension) is a topical quinolone antimicrobial for the treatment of bacterial conjunctivitis, commonly referred to as "pink eye."

Development timeline for Besivance

DateArticle
May 29, 2009Approval Bausch & Lomb Receives FDA Approval of Besivance, New Topical Ophthalmic Antibacterial for the Treatment of Bacterial Conjunctivitis ('Pink Eye')
Dec  5, 2008FDA Advisory Committee Recommends Approval of Bausch & Lomb Besifloxacin Anti-Infective Eye Drop

See also

Besivance (besifloxacin) Consumer information

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer